Natus Medical Incorporated (NASDAQ:NTUS) has been assigned an average broker rating score of 3.00 (Hold) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating.
Zacks has also assigned Natus Medical an industry rank of 94 out of 255 based on the ratings given to its competitors.
Separately, TheStreet upgraded shares of Natus Medical from a “d+” rating to a “c-” rating in a research report on Monday, September 30th.
Shares of NTUS stock traded up $0.41 on Friday, reaching $31.55. 155,945 shares of the stock were exchanged, compared to its average volume of 135,519. The company has a current ratio of 1.87, a quick ratio of 1.36 and a debt-to-equity ratio of 0.12. Natus Medical has a one year low of $22.25 and a one year high of $34.89. The company has a market capitalization of $1.06 billion, a PE ratio of 22.22 and a beta of 0.68. The firm’s 50 day moving average price is $32.42.
Natus Medical (NASDAQ:NTUS) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.36 EPS for the quarter, missing the Zacks’ consensus estimate of $0.38 by ($0.02). Natus Medical had a positive return on equity of 10.43% and a negative net margin of 4.71%. The firm had revenue of $123.46 million during the quarter, compared to analyst estimates of $124.75 million. During the same quarter in the previous year, the business earned $0.40 earnings per share. Natus Medical’s revenue for the quarter was down 5.5% compared to the same quarter last year. As a group, analysts anticipate that Natus Medical will post 1.26 earnings per share for the current year.
Natus Medical Company Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: What are the advantages of the Stochastic Momentum Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.